MAIAMAIA Biotechnology, Inc.

NYSE MAIABiotech.com


$ 2.90 $ 0.26 (9.7 %)    

Friday, 26-Apr-2024 15:58:26 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.94
$ 2.72
$ 0.00 x 0
$ 0.00 x 0
$ 2.71 - $ 3.00
$ 0.82 - $ 3.07
450,546
na
38.99M
$ 0.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-24-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-22-2022 06-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maia-biotechnology-announces-170940--share-purchase-by-director-adelina-louie-in-private-placement

Five independent members of MAIA's Board of Directors purchased shares in the offeringMAIA Biotechnology, Inc., (NYSE:MAIA)...

 maia-biotechnology-announces-133m-private-placement-of-06m-shares-at-2295share

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...

 maia-biotechnology-announces-170940-share-purchase-by-director-stan-smith-phd-in-a-29m-private-placement

Dr. Smith has participated in every MAIA funding roundMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company&#...

 maia-biotechnology-announces-efficacy-of-thio-combination-thio-180mg--cemiplimab-achieved-38-overall-response-rate-in-difficult-to-treat-third-line-non-small-cell-lung-cancer

Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell l...

 maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment-candidates-and-development-pipeline-in-letter-to-shareholders

THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications...

 maia-biotechnology-completes-enrollment-in-thio-101-phase-2-clinical-trial-for-non-small-cell-lung-cancer

Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent i...

 maia-biotechnology-published-findings-regarding-effects-of-thio-for-potential-treatment-of-small-cell-lung-cancer

THIO treatment leads to profound activation of innate and adaptive anti-tumor responsesTHIO depletes cancer initiating cells (C...

 maia-biotechnology-provides-phase-2-clinical-updates-for-lead-anticancer-agent-and-outlines-targeted-milestones-for-2024

Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cell lung cancer (NSCLC) clinical trialM...

 why-wipro-shares-are-trading-higher-by-over-16-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial res...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION